Outlook Therapeutics (OTLK) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 47.7% versus a loss of 55.2%. Over five years, TARA leads with a -61.3% price change compared with -98.7% for OTLK. Protara Therapeutics is the larger company by market cap ($158.7 million vs $139.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | TARA |
|---|---|---|
| Share price | $0.571 | $2.69 |
| Market cap | $139.01M | $158.67M |
| 1-day change | +1.24% | +1.32% |
| YTD return | -64.30% | -50.28% |
| 1-year return | -55.24% | -47.73% |
| 5-year return | -98.66% | -61.26% |
| EPS (TTM) | $-0.70 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $7.82 |
| 52-week low | $0.161 | $2.51 |
| Distance from 52-week high | -77.50% | -65.66% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +780.91% | +857.54% |
| Average volume | 13.33M | 814.80K |
| Shares outstanding | 243.45M | 59.10M |
| Employees | 17 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
OTLK vs TARA FAQ
Which is bigger, Outlook Therapeutics or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $158.67M compared with $139.01M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, OTLK or TARA?
TARA returned -47.73% over the past 12 months, compared with -55.24% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.